147 related articles for article (PubMed ID: 7905363)
1. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.
Isola JJ; Holli K; Oksa H; Teramoto Y; Kallioniemi OP
Cancer; 1994 Feb; 73(3):652-8. PubMed ID: 7905363
[TBL] [Abstract][Full Text] [Related]
2. The neu-oncogene product in serum and tissue of patients with breast carcinoma.
Kath R; Höffken K; Otte C; Metz K; Scheulen ME; Hülskamp F; Seeber S
Ann Oncol; 1993 Aug; 4(7):585-90. PubMed ID: 8103351
[TBL] [Abstract][Full Text] [Related]
3. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
4. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.
Leitzel K; Teramoto Y; Sampson E; Mauceri J; Langton BC; Demers L; Podczaski E; Harvey H; Shambaugh S; Volas G
J Clin Oncol; 1992 Sep; 10(9):1436-43. PubMed ID: 1355522
[TBL] [Abstract][Full Text] [Related]
5. erbB-2 and myc oncoproteins in sera and tumors of breast cancer patients.
Breuer B; De Vivo I; Luo JC; Smith S; Pincus MR; Tatum AH; Daucher J; Minick CR; Miller DG; Nowak EJ
Cancer Epidemiol Biomarkers Prev; 1994; 3(1):63-6. PubMed ID: 7906981
[TBL] [Abstract][Full Text] [Related]
6. Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer.
Kovacević D; Sonicki Z; Kusić Z; Bolanca A; Grubisić G; Lukac M; Lukac J
Int J Colorectal Dis; 2007 Jul; 22(7):827-31. PubMed ID: 17119985
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer.
Nugent A; McDermott E; Duffy K; O'Higgins N; Fennelly JJ; Duffy MJ
Clin Chem; 1992 Aug; 38(8 Pt 1):1471-4. PubMed ID: 1353709
[TBL] [Abstract][Full Text] [Related]
9. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer.
Chariyalertsak S; Sugano K; Ohkura H; Mori Y
Tumour Biol; 1994; 15(5):294-303. PubMed ID: 7991990
[TBL] [Abstract][Full Text] [Related]
10. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse.
Sugano K; Ushiama M; Fukutomi T; Tsuda H; Kitoh T; Ohkura H
Int J Cancer; 2000 Jul; 89(4):329-36. PubMed ID: 10956406
[TBL] [Abstract][Full Text] [Related]
11. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
[TBL] [Abstract][Full Text] [Related]
12. Correlation between serum HER-2 oncoprotein and patients with breast cancer.
Yuan P; Xu BH; Chu DT
Chin Med Sci J; 2004 Sep; 19(3):212-5. PubMed ID: 15506651
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
Shukla S; Singh BK; Pathania OP; Jain M
Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients.
Fehm T; Gebauer G; Jäger W
Breast Cancer Res Treat; 2002 Sep; 75(2):97-106. PubMed ID: 12243512
[TBL] [Abstract][Full Text] [Related]
15. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study.
Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT
Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088
[TBL] [Abstract][Full Text] [Related]
16. ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.
Meenakshi A; Kumar RS; Kumar NS
J Immunoassay Immunochem; 2002; 23(3):293-305. PubMed ID: 12227416
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
Leitzel K; Teramoto Y; Konrad K; Chinchilli VM; Volas G; Grossberg H; Harvey H; Demers L; Lipton A
J Clin Oncol; 1995 May; 13(5):1129-35. PubMed ID: 7738618
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
19. Serum c-erb B2 oncoprotein levels are elevated in recurrent and metastatic breast cancer.
Yasasever V; Dincer M; Camlica H; Duranyildiz D; Dalay N
Clin Biochem; 2000 Jun; 33(4):315-7. PubMed ID: 10936592
[No Abstract] [Full Text] [Related]
20. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Muñoz M; Farrus B; Latre ML; Gimenez N; Hage M; Estape J; Ballesta AM
Anticancer Res; 1996; 16(4B):2295-300. PubMed ID: 8694559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
